{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:05:04Z","timestamp":1784304304591,"version":"3.55.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2017,11,18]],"date-time":"2017-11-18T00:00:00Z","timestamp":1510963200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravenous (IV) iron can modulate fibroblast growth factor 23 (FGF23) concentrations and cause transient but significant hypophosphataemia. However, it is unknown what other markers might be involved, especially in different patient groups. This study aimed to determine changes in bone and haematinic biomarkers following IV ferric carboxymaltose (FCM) and to identify risk factors for hypophosphataemia in pregnant subjects and those with chronic kidney disease (CKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Changes in bone [serum FGF23, fractional excretion of phosphate urinary fractional excretion of phosphate (FEPi), serum phosphate and serum vitamin D derivatives] and haematinic [plasma hepcidin, serum ferritin and transferrin saturation (TSAT)] biomarkers after 1\u2009g of IV FCM were followed in iron-deficient pregnant and CKD patients and compared with controls (estimated glomerular filtration rate\u2009&amp;gt;\u200960\u2009mL\/min\/1.73\u00a0m2). Data were collected at baseline and up to 42\u2009days after infusion. Risk factors for post-FCM hypophosphataemia were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-five subjects completed the study (control, n\u2009=\u200920; pregnant, n\u2009=\u200920; CKD, n\u2009=\u200925). A uniform but variable increase across groups was seen in intact FGF23 (peak Day 2), whereas c-terminal FGF23 varied markedly. Trough serum phosphate timed with the peak FEPi at Day 7, recovering by Day 21 in the pregnant group and Day 42 in other groups. Independent predictors of a low phosphate nadir included baseline phosphate, FEPi and weight-adjusted FCM dose. All groups showed an early and marked increase in plasma hepcidin (peak Day 2), serum ferritin and TSAT (peak Day 7 for both).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Changes in bone and haematinic biomarkers differ between patient groups following IV FCM. For patients with lower serum phosphate concentrations, limiting the dose and measuring levels 7\u2009days after administration may mitigate clinically significant hypophosphataemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfx310","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T15:39:12Z","timestamp":1507649952000},"page":"1628-1635","source":"Crossref","is-referenced-by-count":16,"title":["A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy"],"prefix":"10.1093","volume":"33","author":[{"given":"Louis L","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, Eastern Health, Melbourne, VIC, Australia"},{"name":"Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Eastern Health, Melbourne, VIC, Australia"},{"name":"Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie M","family":"Troster","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Eastern Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette B","family":"Kent","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Eastern Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Eastern Health, Melbourne, VIC, Australia"},{"name":"Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain C","family":"Macdougall","sequence":"additional","affiliation":[{"name":"Renal Unit, King\u2019s College Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence P","family":"McMahon","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Eastern Health, Melbourne, VIC, Australia"},{"name":"Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"key":"2025102312504297600_gfx310-B1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10198-013-0533-9","article-title":"Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data","volume":"15","author":"Brock","year":"2014","journal-title":"Eur J Health Econ"},{"key":"2025102312504297600_gfx310-B2","doi-asserted-by":"crossref","first-page":"e45604","DOI":"10.1371\/journal.pone.0045604","article-title":"Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency","volume":"7","author":"Calvet","year":"2012","journal-title":"PLoS One"},{"key":"2025102312504297600_gfx310-B3","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study","volume":"94","author":"Schouten","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2025102312504297600_gfx310-B4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1471-2369-14-167","article-title":"Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study","volume":"14","author":"Prats","year":"2013","journal-title":"BMC Nephrol"},{"key":"2025102312504297600_gfx310-B5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2025102312504297600_gfx310-B6","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","article-title":"Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia","volume":"45","author":"Shimizu","year":"2009","journal-title":"Bone"},{"key":"2025102312504297600_gfx310-B7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","article-title":"Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease","volume":"23","author":"Wolf","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025102312504297600_gfx310-B8","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1080\/00365521.2016.1196496","article-title":"High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23","volume":"51","author":"Dahlerup","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"2025102312504297600_gfx310-B9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000440968","article-title":"Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency","volume":"131","author":"Iguchi","year":"2015","journal-title":"Nephron"},{"key":"2025102312504297600_gfx310-B10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000327019","article-title":"Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients","volume":"33","author":"Takeda","year":"2011","journal-title":"Am J Nephrol"},{"key":"2025102312504297600_gfx310-B11","article-title":"Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal FGF23 levels of maintenance hemodialysis patients","author":"Yamashita","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"2025102312504297600_gfx310-B12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12882-016-0391-7","article-title":"Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial","volume":"17","author":"Roberts","year":"2016","journal-title":"BMC Nephrol"},{"key":"2025102312504297600_gfx310-B13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025102312504297600_gfx310-B14","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/bcp.13189","article-title":"Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions","volume":"83","author":"Bager","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2025102312504297600_gfx310-B15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025102312504297600_gfx310-B16","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1210\/jc.2011-1239","article-title":"Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans","volume":"96","author":"Imel","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2025102312504297600_gfx310-B17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ejcn.2016.217","article-title":"Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients","volume":"71","author":"Tan","year":"2017","journal-title":"Eur J Clin Nutr"},{"key":"2025102312504297600_gfx310-B18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1258\/acb.2008.008151","article-title":"Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia","volume":"46(Pt 2)","author":"Schouten","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"2025102312504297600_gfx310-B19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2169\/internalmedicine.51.7450","article-title":"Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide","volume":"51","author":"Yamamoto","year":"2012","journal-title":"Intern Med"},{"key":"2025102312504297600_gfx310-B20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/2042018816678363","article-title":"Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature","volume":"8","author":"Bishay","year":"2017","journal-title":"Ther Adv Endocrinol"},{"key":"2025102312504297600_gfx310-B21","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00467-012-2175-z","article-title":"Phosphate homeostasis and its role in bone health","volume":"27","author":"Penido","year":"2012","journal-title":"Pediatr Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/33\/9\/1628\/25590870\/gfx310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/33\/9\/1628\/25590870\/gfx310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:52:02Z","timestamp":1761238322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/33\/9\/1628\/4641622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,11,17]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfx310","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2017,11,17]]}}}